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INTRODUCTION
The symptoms of hyperprolactinemia in women mainly
result from changes in the release of gonadotropins and the
consequent repercussions on ovarian function.1-3 Metoclo-
pramide is a hyperprolactinemic drug that is used as an
antiemetic agent.4,5 In female mice, metoclopramide-induced
hyperprolactinemia causes changes in the reproductive
system, mainly in ovarian function and the endometrium.6-10
While there is extensive data regarding prolactin regulation
and hyperprolactinemic states, the direct effects of metoclo-
pramide on the morphological and functional aspects of
pituitary cells remain unknown. Therefore we have evaluated
the histomorphological and immunohistochemical changes
in lactotrophs of female mice upon treatment with
metoclopramide.
MATERIALS AND METHODS
Eighty adult, virgin female mice of the Swiss EPM-1 strain
were kept on food and water ad libitum at room temperature
(22 C˚) and under artificial light with a photoperiod of
12 hours (lights on 7 a.m.–7 p.m.). The animals were
randomly divided into 2 groups of 40 animals each: control
(Ctr), which were injected daily with drug vehicle (0.2 ml of
saline solution), and experimental (HPrl), treated with
metoclopramide (6.7 mg/g daily).6-10 Injections were made
by the subcutaneous route at 11 a.m., and the treatments
lasted 50 days. The experimental protocol was approved
(Report No. 0809/04) by the UNIFESP-EPM Review Board.
On day 50, 1 h after the last injection, colpocytological
examination of vaginal smears was carried out for all
animals, which were in each of the 4 phases of the estrous
cycle (10 mice per phase in both Ctr and HPrl groups),
before they were euthanized by decapitation. The animals
not typified remained on treatment and were euthanized
once their phase was diagnosed. Hormone levels were
measured in blood samples taken immediately after
euthanasia. Pituitary glands were carefully dissected out
and immediately immersed in Bouin’s liquid for further
histological processing.
Serum 17b-estradiol and progesterone was determined
using their respective kits (ICN Biomedicals Inc., Costa Mesa,
CA, USA). The samples were assayed in duplicate and
processed on the same day. The detection limits for estradiol
and progesterone were approximately 0.1 pg/ml and
0.15 ng/ml, respectively. Crossreactivity with other steroids
for both assays was less than 0.01%. Serum prolactin (PRL)
was determined using a mouse PRL radioimmunoassay kit.
For immunohistochemistry analyses, pituitaries were fixed
in Bouin’s fluid for 6 hours and embedded in paraffin; 5-mm
sections were microwaved in 1 M sodium citrate buffer
(pH 6.0) for 8 min in order to retrieve the antigen.11 After
treatment with 0.1% Triton X-100 for 10 min, endogenous
peroxydase activity was blockedwith 0.3%H2O2 in methanol
for 30 min. Antibody non-specific binding was blocked with
normal goat serum (VECTASTAIN Elite ABC kit, Vector
Laboratories) for 20 min at room temperature. The sections
were then incubated overnight with primary antibody at 4–
8 C˚ (15600, A0569, Dako Cytomation). After washing in PBS,
sections were incubated with the secondary antibody, rabbit
anti-chicken IgG (15800, DakoCytomation) for 15 min.
Reaction products were visualized by using 3,39-diamino-
benzidine (DAB, Sigma Chemical Co). The negative control
was prepared by incubating sections with rabbit immuno-
globulin fraction (DAKO Cytomation) instead of the primary
antibody. Sections were counterstained with hematoxylin.
The number and the nuclear volume of prolactin-immuno-
labeled cells (lactotroph cells) were evaluated in images taken
by a high-resolution camera (AxioCam MRC, Carl Zeiss) at a
final magnification of x400. The camera was connected to a
computer coupled to a light microscope (Axiolab Standard 2.0,
Carl Zeiss) and images were analyzed using REL AxionVision
4.6 software (Carl Zeiss). To evaluate the number of lactotroph
cells, 8 fields were captured for every sample with a x40
objective (37,745.55 mm2 field area) and a total of 80 fields were
analyzed for each group (total area for group =299,644.00 mm2).
To calculate nuclear volume, the largest (a) and the shortest (b)
nuclear diameters from 50 lactotroph cells for every animal
were measured at a final magnification of x1000 and then used
in the formula V=a.b2/1,91.12 The results were analyzed by
analysis of variance (ANOVA) followed by the Kruskal-Wallis
test (p,0.05).
RESULTS
The level of 17b-estradiol was higher in the control (Ctr)
group than in the HPrl group in all phases, particularly
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Table 1 - Circulating hormones and pituitary morphometric data throughout the estrous cycle in female control mice
(Ctr) or mice rendered hyperprolactinemic (HPrl) by treatment with metoclopramide.
Proestrus Estrus Metaestrus Diestrus
Ctr HPrl Ctr HPrl Ctr HPrl Ctr HPrl
Serum hormones:
17b-Estradiol (pg/mL) 121.2¡8.2a 90.3¡3.9b 92.3¡2.8 45.3¡3.1b 65.8¡5.7 55.3¡2.8b 72.4¡3.5 59.3¡4.2b
Progesterone (ng/mL) 11.6¡0.5a 3.7¡0.1b 5.7¡0.4 2.7¡0.2b 6.1¡0.1 1.9¡0.4b 7.7¡0.2 2.9¡0.3b
Prolactin (ng/mL) 44.1¡7.1a 301.2¡42.1b 28.8¡8.1 274.3¡35.5b 20.8¡5.3 264.1¡42.9b 19.3¡5.6 269.1¡42.1b
Pituitary lactotrophs:
Density (cells/1000 mm2) 9.1¡0.3 12.2¡0.1b 8.4¡0.1 10.2¡0.2b 8.0¡0.2 11.0¡0.1b 8.1¡0,3 9.7¡0.2b
Cell volume (mm3) 151,33¡7.1a 176.2¡9.1b 128,58¡7.1 169.3¡8.5b 102.48¡5.3 166.1¡8.9b 106.1¡4.6 165.1¡8.1b
Data are shown as mean ¡ SD.
aindicates p,0.05 when compared to other phases of the Ctr groups.
bindicates p,0.05 when compared to the Ctr group in each estrous cycle phase.
Fig. 1 - Immunohistochemical localization of prolactin in adenohypophyseal lactotrophs in female control (Ctr) mice or mice treated
with metoclopramide (HPrl) in the estrous phase. Arrows indicate prolactin-positive cells. P = Proestrus; E = Estrus, M = Metaestrus; D =
Diestrus. Scale bar = 20 mm.
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during the proestrous phase (Table 1). However, the level of
progesterone was higher in the Ctr group (Table 1). Also,
the highest level of prolactin in the HPrl group occurred
during the proestrus phase (Table 1). PRL immunolabeling
of pituitary glands revealed markedly stronger expression
in the metoclopramide group (Fig. 1). Metoclopramide-
treated female mice had significant increases in the number
and the volume of lactotroph cells of the pituitary gland
during all phases of the estrous cycle (Table 1).
DISCUSSION
In the neuroendocrine axis, dysfunction of hypothalamic
dopamine or its pituitary receptors leads to hyperprolacti-
nemia and reproductive disturbances.13,14 The PRL secre-
tory profile is well established in female mice; circulating
PRL remains low in normal cycling animals throughout
most of the estrous cycle. There is one prominent PRL surge
at proestrus, which is coincident with luteinizing hormone
(LH), for a period of 4–5 days.3 Our serum PRL results also
revealed higher levels in Ctr proestrus animals than control
rats in other phases.
Metoclopramide has been used to study the effects of the
elevation of prolactin (PRL) plasma levels on the body for
many years15. However, the pituitary synthesizes and
secretes several distinct hormones. Therefore, we employed
an immunohistochemical PRL marker to identify lactotroph
cells.16
We found that metoclopramide not only increased the
number but also stimulated the metabolic activity of
lactotrophs, as indicated by the enlarged nuclear volumes
in hyperprolactinemic animals irrespective to the phase of
the estrous cycle. Given the existence of a definite relation-
ship between nuclear volume and cell metabolism,12 it is
conceivable that the observed increase of circulating PRL is
due to an increase of the number and the activity of
lactotrophs. Interestingly, metoclopramide-treated animals
showed high levels of circulating PRL and increased
number and nuclear volumes of lactotrophs, and this profile
did not change throughout the phases of the estrous cycle.
Dopamine and its agonists regulate many systems
through stimulation of adrenergic and dopaminergic recep-
tors and also regulate PRL production.17 As a D2 receptor
antagonist, metoclopramide affects PRL secretion.7,8,13,18
The long and short isoforms of the dopamine receptor
(D2L and D2S) exhibit similar pharmacological properties
and are co-expressed in the same cells.19 The D2L isoform is
predominant in the rat pituitary, striatum, and olfactory
tubercle, whereas D2S is more abundant in the hypothala-
mus.20-22 Activation of either isoform in rat lactotrophs
mediates dopamine suppression of the PRL gene.23
While PRL directly inhibits secretion of gonadotropins
from the anterior pituitary, there is accumulating evidence
that PRL also exerts a direct inhibitory effect on gonado-
tropin actions in the ovary24. Physiological levels of PRL
suppress follicle-stimulating hormone (FSH)-induced estra-
diol production through a reduction in aromatase expres-
sion and PRL increases progesterone production by
augmenting StAR, P450scc, and 3bHSD expression in
granulosa cells.25 However, hyprolactinemia may inhibit
GnRH release and reduce ovulation, explaining the reduc-
tion in progesterone.7,8,24 Also, metoclopramide-induced
hyperprolactinemia correlates with a low number of luteal
bodies, which are ovarian structures responsible for
progesterone production.7
The central PRL-secretion regulator dopamine inhibits
lactotroph proliferation and decreases the size of hyper-
trophied lactotrophs.26,27 Our results show that daily
treatment with metoclopramide induces a consistent hyper-
prolactinemic state and increases the number and the
volume of lactotrophs. Thus, our data suggest that besides
the increase of pituitary PRL secretion, significant prolifera-
tion of the pituitary gland occurrs. If this process were to
continue, we would predict an evolution towards pituitary
gland tumorigenesis. We also observed a significant
decrease in progesterone levels coexisted with PRL serum
elevation. Overall, these disturbances may have deleterious
effects on ovarian function,7 endometrial tissue,9 and
embryo implantation.8 Finally, hyperprolactinemia caused
by metoclopramide in mice is due to an increase in the
number and activity of lactotrophs and these alterations
seem to be independent of the cycle phase.
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